More patients today and tomorrow: a company 100% committed to the future of proton therapy
Proton Therapy offers the possibility to treat cancer cases with a lower integral dose of radiation. This extraordinary modality helps to significantly reduce the dose to healthy tissues and decrease the risk of side effects.
Continue reading
The time to 1st patient is the number of months required to have the facility ready to treat the first patient from Building Occupancy Date. A patient treated with proton therapy can have 5 to 35 treatments, depending on the case.
At IBA, we are committed to make proton therapy accessible to more patients worldwide. Today, very few patients have benefited from proton therapy due to the lack of centers equipped with the appropriate equipment. IBA is committed to changing this by making proton therapy more available to patients, as well as more affordable to health care systems.
With more than 25 years of experience in medical accelerators, IBA, the market leader, has designed and equipped the majority of clinically operating proton therapy centers around the world.
You benefit from a learning curve that allows us to significantly reduce the time required to reach first patient treatments.
The know-how and consulting services you can benefit from include:
Facts:
IBA has installed over 50% of clinically operating proton therapy centers worldwide with over 20 projects that are already operational or at various stages of development.
Today IBA is the sole player in the PT market that can enable its new customers to leverage the experience of its users’ community. For example, IBA organizes annually the “IBA Proteus User Meeting”.
It is a meeting that brings together clinicians, physicists, therapists and administrators from all sites installed by IBA, joined by IBA experts. This platform gives IBA a strong indication of how working together constructively can lay the foundation for advancing proton therapy as a universally accepted clinical treatment.
Years of collaboration between IBA and its renowned clinical customers helped treat over 20,000 patients worldwide. Those patients benefited from a compassionate cancer treatment that ensured a better quality of life during and after treatment.
Our customers benefit from a learning curve of over 20 years that allowed IBA to significantly reduce the time required to reach “first patient” treatment. With more than 20 proton therapy centers around the world, IBA is the undisputed leader in this advanced technology.
Patients treated with proton therapy
Having pioneered the field of proton therapy to become the worldwide leader today, IBA remains committed to following this path. We aim to offer our customers ever more flexible and accessible state-of-the-art proton therapy solutions and make this extraordinary treatment modality available to more and more patients worldwide.
Proton therapy is and will remain our focus and the key driver of our company growth.
Facts:
Over the years and through countless efforts in R&D and partnership with its customers, IBA has played an active role in developing proton therapy around the globe.
We deeply believe that proton therapy will help control cancer worldwide in the most compassionate way possible.
Facts:
Years of continuous improvement and innovations enable IBA to meet the highest standard of quality at all levels of the organization. To ensure that the quality is well managed, IBA is certified ISO 13485 while meeting all quality requirements of regional regulatory bodies (FDA, CE marking, SFDA, KFDA …).
IBA leads the world in regulatory clearance for proton therapy systems with FDA clearance in the United States, CE marking in Europe and SFDA clearance in China. This together with experience gained aver 20+ projects worldwide ensures a safe, fast path to treatment while lowering substantially the technical and financial risk of the project.
Facts:
Proton Therapy offers the possibility to treat cancer cases with a lower integral dose of radiation. This extraordinary modality helps to significantly reduce the dose to healthy tissues and decrease the risk of side effects.
We, at IBA, deeply believe that proton therapy will help control and cure cancer worldwide in a most empathetic way. If given a choice, patients choose proton therapy.
At IBA, we have already developed 20+ Proteus proton therapy centers with renowned institutions worldwide. Today, we are more committed than ever to develop and deliver ever more accessible proton therapy solutions. Our experience in treating 20.000+ patients over the years enables our experts to make proton therapy more compact, more affordable and thus more accessible to patients worldwide.
As CEO of IBA, my number one priority is to bring ProteusONE*, IBA’s compact proton therapy solution, to the medical community without compromising on treatment options. I deeply believe that ProteusONE will change the way we treat cancer. Protons are possible.
Olivier Legrain
Chief Executive Officer, IBA
* Some features are under development and are subject to review by competent authorities (FDA, Notified bodies, et al...).
© IBA 2013 | All rights reserved |
Site map |
